Category
81 articles — page 4 of 7
April 13, 2026
Home narrowband UVB is one of the most effective options available to vitiligo patients — but getting the dose, timing, and safety protocol right matters. This guide covers how to use a home NbUVB device safely and effectively, including starting doses, progression, side effects to watch for, and how to protect sensitive areas.
April 13, 2026
For many patients, stopping vitiligo from spreading is a more urgent goal than repigmentation. Here is what the evidence shows works for stabilization — and what the triggers are that drive active spread.
April 13, 2026
Can you take a supplement to restore melanin in vitiligo? Here is what the research says about every supplement category — what has evidence, what is pure marketing, and what you should actually consider.
April 13, 2026
Ruxolitinib cream works well on the face but poorly on hands and feet. Here is why acral vitiligo responds differently and what combination strategies actually move the needle.
April 13, 2026
Ruxolitinib cream (Opzelura) combined with narrowband UVB is emerging as the most effective non-surgical approach for vitiligo repigmentation. Here is the evidence behind the combination, the practical protocol, and what you can realistically expect.
April 13, 2026
Vitiligo patients need daily sunscreen, and the guidance changes during pregnancy. Here is which sunscreen ingredients are considered safe in pregnancy, which to avoid, and the practical recommendations for protecting depigmented skin while pregnant.
April 13, 2026
Not all vitiligo patches respond the same way. The face responds well to most treatments. The hands and feet are notoriously resistant. Here is a body-area breakdown of what works where, why location matters, and how to set realistic expectations for each site.
April 13, 2026
A patient-friendly side-by-side of every major vitiligo treatment — how they work, what they cost, who they suit, and what the evidence actually says about each one.
March 29, 2026
Vitiligo patients show consistent gut microbiome differences compared to healthy controls. Whether fixing that gap changes outcomes is less clear. Here is the honest picture.
March 29, 2026
Opzelura is the first FDA-approved topical treatment specifically for vitiligo. Here is everything patients need to know: how it works, who responds, realistic timelines, cost, and what to do if insurance denies it.
March 29, 2026
Opzelura is frequently denied on first submission. Most denials can be successfully appealed. Here is the exact process, what your dermatologist needs to write, and the argument that works.
March 29, 2026
AbbVie submitted upadacitinib for FDA and EMA approval in February 2026. It is oral, systemic, and could address body vitiligo where topical treatments fall short.
